title: Decline in age-dependent, MK801-induced injury coincides with developmental switch in parvalbumin expression: somatosensory and motor cortex.
abstract: MK801-induced activation of caspase-3 is developmentally regulated, peaking at postnatal day (P) 7 and decreasing with increasing postnatal age thereafter. Further, at P7, cells displaying activation of caspase-3 lack expression of calcium binding proteins (CaBPs). To further explore this relationship, we investigated postnatal expression of calbindin (CB), calretinin (CR) and parvalbumin (PV) in two brain regions susceptible to MK801-induced injury, the somatosensory cortex (S1) and layer II/III of motor cortex (M1/M2). Expression of CB and especially PV was low to absent prior to P7 but substantially increased from P7 through to P21 and adulthood. In contrast, CR expression was more variable at early developmental ages, stabilized to lower levels after P7 and showed a marked decline by P21. The results suggest that not only does calcium buffering capacity increase developmentally but also acquisition of enhanced buffering may be one mechanism by which neurons survive agent-induced alterations in calcium homeostasis.
authors.affiliation: Neurobiology & Anatomy, Wake Forest University Medical School, Medical Center Boulevard, Winston Salem, NC 27157-1010, USA. cltome@wfubmc.edu
authors.forename: Carla M
authors.initials: CM
authors.lastname: Lema Tomé
authors.forename: Ryan
authors.initials: R
authors.lastname: Miller
authors.forename: Clayton
authors.initials: C
authors.lastname: Bauer
authors.forename: Chelsey
authors.initials: C
authors.lastname: Smith
authors.forename: Kaitlin
authors.initials: K
authors.lastname: Blackstone
authors.forename: Adam
authors.initials: A
authors.lastname: Leigh
authors.forename: Jamie
authors.initials: J
authors.lastname: Busch
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Turner
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects; D064032:Calbindin 2; D064026:Calbindins; D002118:Calcium / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D006706:Homeostasis / Q000187:drug effects; D009044:Motor Cortex / Q000187:drug effects* / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010320:Parvalbumins / Q000378:metabolism*; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D013003:Somatosensory Cortex / Q000187:drug effects* / Q000473:pathology
chemical_list: D064032:Calbindin 2; D064026:Calbindins; D018691:Excitatory Amino Acid Antagonists; D010320:Parvalbumins; D064030:S100 Calcium Binding Protein G; D016291:Dizocilpine Maleate; D053148:Caspase 3; D002118:Calcium